Bimatoprost Ophthalmic Solution clinical trials
A product of Bimatoprost; its studies count on that page too.
How each study uses Bimatoprost Ophthalmic Solution is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Bimatoprost Ophthalmic Solution studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 16 Mar 2001 · LUMIGAN · NDA 021275 (FDA, Drugs@FDA; as Bimatoprost)
- European Union
- 8 Mar 2002 · Lumigan · EMEA/H/C/000391 (EMA; as Bimatoprost)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2010 (3)
| Year | Studies |
|---|---|
| 2010 | 3 |
| 2011 | 2 |
| 2014 | 1 |
| 2016 | 2 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 1
Allergan (7) · YS Life Science Co., Ltd. (1) · Amneal Pharmaceuticals, LLC (1) · Jonsson Comprehensive Cancer Center (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- A dosage form of Bimatoprost
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test Bimatoprost Ophthalmic Solution, phase 3 first.
- Nov 2027A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular HypertensionPhase 3 · YS Life Science Co., Ltd.
Studies
Open first, then newest update. How each study uses Bimatoprost Ophthalmic Solution is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular HypertensionRecruitingPhase 3YS Life Science Co., Ltd.NCT07661329Written as Bimatoprost ophthalmic solution 0.01% YSBP
- A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both EyesRecruitingPhase 1Amneal Pharmaceuticals, LLCNCT06267274Written as Bimatoprost Ophthalmic Solution, 0.01%
- Bimatoprost Ophthalmic Solution in Increasing Eyebrow and Eyelash Growth in Patients Who Have Undergone Chemotherapy for Breast Cancer and in Healthy ParticipantsWithdrawnNot applicableJonsson Comprehensive Cancer CenterNCT00999557Written as bimatoprost ophthalmic solution
- Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in ChildrenCompletedPhase 4AllerganNCT01023841Written as bimatoprost ophthalmic solution 0.03%
- Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)CompletedPhase 4AllerganNCT02176356Written as bimatoprost ophthalmic solution 0.03%
- Efficacy and Safety of COMBIGAN® in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG)CompletedPhase 4AllerganNCT02863705Written as bimatoprost ophthalmic solution 0.01%
- Safety and Efficacy of LUMIGAN® RC Versus DuoTrav® in Patients Who Require Further Intraocular Pressure (IOP) ReductionCompletedPhase 4AllerganNCT01547598Written as Bimatoprost ophthalmic solution 0.01%
- Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash ProminenceCompletedPhase 4AllerganNCT01448525Written as bimatoprost ophthalmic solution 0.03%
- Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedPhase 4AllerganNCT01253902Written as bimatoprost ophthalmic solution 0.01%
- Safety and Efficacy of Bimatoprost Ophthalmic Solution in Increasing Eyelash ProminenceCompletedPhase 2AllerganNCT01064882Written as bimatoprost ophthalmic solution 0.005%
Given beside what is tested · 1 — Bimatoprost Ophthalmic Solution is usual care or a partner of the new treatment
As the comparator · 5 — what is tested is compared with Bimatoprost Ophthalmic Solution
- Safety and Efficacy of Bimatoprost Timolol Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular HypertensionCompletedNot applicableAllerganNCT01068964Written as 0.03% Bimatoprost Ophthalmic Solution and 0.5% Timolol Ophthalmic Solution
- A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular HypertensionCompletedPhase 2AllerganNCT01863953Written as Bimatoprost Ophthalmic Solution 0.01%
- Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular HypertensionCompletedPhase 2AllerganNCT01110499Written as bimatoprost ophthalmic solution 0.03%
- Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle GlaucomaCompletedPhase 1/2AllerganNCT00809848Written as bimatoprost ophthalmic solution 0.03%
- Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic SolutionCompletedPhase 2AllerganNCT01001195Written as bimatoprost ophthalmic solution 0.03%